Free tool
FAERS Monitor: Aprepitant
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218754 or its brand name (Aprepitant, Aprepitant). Reports on generic versions are filed under their own applications.
Reports
7,375
Serious
7,064
96% of reports
Hospitalization
4,447
Death reported
1,464
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,287
- nausea1,105
- pyrexia921
- off label use872
- alopecia823
- dyspnoea806
- diarrhoea770
- rash764
- vomiting702
- hypersensitivity701
- pain690
- infusion related reaction689
- decreased appetite684
- stomatitis663
- pruritus662
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 15 |
| 2006 | 28 |
| 2007 | 24 |
| 2008 | 29 |
| 2009 | 48 |
| 2010 | 66 |
| 2011 | 105 |
| 2012 | 141 |
| 2013 | 169 |
| 2014 | 160 |
| 2015 | 228 |
| 2016 | 393 |
| 2017 | 164 |
| 2018 | 340 |
| 2019 | 413 |
| 2020 | 488 |
| 2021 | 662 |
| 2022 | 634 |
| 2023 | 748 |
| 2024 | 1,025 |
| 2025 | 889 |
| 2026 | 599 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,784 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| stomatitisSignal | 663 | 31.5 | 29.3 | 19,397 |
| infusion related reactionSignal | 689 | 29.9 | 27.9 | 19,108 |
| alopeciaSignal | 823 | 12.0 | 11.2 | 8,329 |
| hypersensitivitySignal | 701 | 10.8 | 10.1 | 6,261 |
| decreased appetiteSignal | 684 | 8.4 | 7.8 | 4,502 |
| pyrexiaSignal | 921 | 7.6 | 7.2 | 5,354 |
| rashSignal | 764 | 5.0 | 4.7 | 2,492 |
| pruritusSignal | 662 | 4.9 | 4.6 | 2,098 |
| fatigueSignal | 1,287 | 4.7 | 4.5 | 3,909 |
| vomitingSignal | 702 | 4.3 | 4.0 | 1,787 |
| dyspnoeaSignal | 806 | 4.1 | 3.8 | 1,908 |
| nauseaSignal | 1,105 | 4.0 | 3.8 | 2,562 |
| diarrhoeaSignal | 770 | 3.4 | 3.2 | 1,345 |
| painSignal | 690 | 3.2 | 3.0 | 1,075 |
| off label useSignal | 872 | 2.8 | 2.7 | 1,083 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.